WO2003052070A3 - Vps41s as modifiers of cell death and methods of use - Google Patents

Vps41s as modifiers of cell death and methods of use Download PDF

Info

Publication number
WO2003052070A3
WO2003052070A3 PCT/US2002/039896 US0239896W WO03052070A3 WO 2003052070 A3 WO2003052070 A3 WO 2003052070A3 US 0239896 W US0239896 W US 0239896W WO 03052070 A3 WO03052070 A3 WO 03052070A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell death
methods
vps41s
modifiers
vps41
Prior art date
Application number
PCT/US2002/039896
Other languages
French (fr)
Other versions
WO2003052070A2 (en
Inventor
Michael A Costa
Dianne Parry
Changyou Chen
Original Assignee
Exelixis Inc
Michael A Costa
Dianne Parry
Changyou Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Michael A Costa, Dianne Parry, Changyou Chen filed Critical Exelixis Inc
Priority to AU2002359696A priority Critical patent/AU2002359696A1/en
Publication of WO2003052070A2 publication Critical patent/WO2003052070A2/en
Publication of WO2003052070A3 publication Critical patent/WO2003052070A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Human VPS41 genes are identified as modulators of the cell death pathway, and thus are therapeutic targets for disorders associated with defective cell death function. Methods for identifying modulators of cell death, comprising screening for agents that modulate the activity of VPS41 are provided.
PCT/US2002/039896 2001-12-13 2002-12-12 Vps41s as modifiers of cell death and methods of use WO2003052070A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002359696A AU2002359696A1 (en) 2001-12-13 2002-12-12 Vps41s as modifiers of cell death and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34030901P 2001-12-13 2001-12-13
US60/340,309 2001-12-13

Publications (2)

Publication Number Publication Date
WO2003052070A2 WO2003052070A2 (en) 2003-06-26
WO2003052070A3 true WO2003052070A3 (en) 2003-11-20

Family

ID=23332796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039896 WO2003052070A2 (en) 2001-12-13 2002-12-12 Vps41s as modifiers of cell death and methods of use

Country Status (2)

Country Link
AU (1) AU2002359696A1 (en)
WO (1) WO2003052070A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284298A2 (en) * 2001-07-27 2003-02-19 Warner-Lambert Company Identification and use of molecules implicated in pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284298A2 (en) * 2001-07-27 2003-02-19 Warner-Lambert Company Identification and use of molecules implicated in pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DARSOW T. ET AL.: "vPs41p Function in the alkaline phosphatase pathway requires homo-oligomerization and interaction with AP-3 through two distinct domains", MOLECULAR BIOLOGY OF THE CELL, vol. 12, no. 1, January 2001 (2001-01-01), pages 37 - 51, XP002967153 *
RADISKY D. ET AL.: "Characterization of VPS41, a gene required for vascuolar trafficking and high-affinity iron transport in yeast", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 11, 27 May 1997 (1997-05-27), pages 5662 - 5666, XP002967155 *
WARNER T. ET AL.: "The light gene of drosophilia melanogaster encodes a homologue of VPS41, a yeast gene involved in cellular-protein trafficking", GENOME, vol. 41, no. 2, 1998, pages 236 - 243, XP002967154 *

Also Published As

Publication number Publication date
WO2003052070A2 (en) 2003-06-26
AU2002359696A8 (en) 2003-06-30
AU2002359696A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
WO2002099059A3 (en) U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099074A8 (en) Slc7s as modifiers of the p53 pathway and methods of use
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074672A3 (en) Crebpas as modifiers of cell death pathways and methods of use
WO2003033656A3 (en) MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
WO2003066811A3 (en) Msrebps as modifiers of the srebp pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP